Niagen Bioscience, Inc. Common Stock NAGE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Analytical Reference Standards and Services segment | $423K— | —— | $772K-3.4% | $799K-1.5% | $811K— | |
| Consumer Products segment | $22.41M— | —— | $26.02M+14.6% | $22.7M+5.6% | $21.5M— | |
| Corporate and other | $74K— | —— | —— | —— | —— | |
| Ingredients segment | $8.56M— | —— | $7.2M-5.5% | $7.62M-6.7% | $8.17M— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Gross Profit by Business | ||||||
| Analytical Reference Standards and Services segment | $115K— | —— | $218K+29.0% | $169K0.0% | $169K— | |
| Consumer Products segment | $14.82M— | —— | $17.46M+14.5% | $15.25M+8.2% | $14.09M— | |
| Ingredients segment | $5.01M— | —— | $4.25M-11.6% | $4.81M-5.1% | $5.07M— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Operating Income (Loss) by Business | ||||||
| Analytical Reference Standards and Services segment | $71K— | —— | $138K+56.8% | $88K+41.9% | $62K— | |
| Consumer Products segment | $4.64M— | —— | $7.42M+23.7% | $6M+8.9% | $5.51M— | |
| Ingredients segment | $4.54M— | —— | $3.8M-12.8% | $4.36M-8.2% | $4.75M— | |
| Pharmaceuticals segment | -$468K— | —— | —— | —— | -$368K+16.3% | |
| Selling by Business | ||||||
| Analytical Reference Standards and Services segment | $44K-45.0% | $80K+1.3% | $79K-2.5% | $81K-24.3% | $107K-13.0% | |
| Consumer Products segment | $2.73M-2.4% | $2.79M+0.2% | $2.79M+4.1% | $2.68M+6.8% | $2.51M-5.4% | |
| Ingredients segment | $94K+88.0% | $50K+31.6% | $38K+443% | $7K-85.7% | $49K+48.5% | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Operating Expenses by Business | ||||||
| Analytical Reference Standards and Services segment | $44K— | —— | $80K-1.2% | $81K-24.3% | $107K— | |
| Consumer Products segment | $10.17M— | —— | $10.03M+8.5% | $9.24M+7.7% | $8.58M— | |
| Ingredients segment | $470K— | —— | $450K0.0% | $450K+41.1% | $319K— | |
| Pharmaceuticals segment | $468K— | —— | —— | —— | $368K-16.3% | |
| Cost of Sales by Business | ||||||
| Analytical Reference Standards and Services segment | $308K— | —— | $554K-12.1% | $630K-1.9% | $642K— | |
| Consumer Products segment | $7.6M— | —— | $8.56M+14.9% | $7.45M+0.6% | $7.41M— | |
| Ingredients segment | $3.56M— | —— | $2.94M+4.8% | $2.81M-9.4% | $3.1M— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Marketing by Business | ||||||
| Analytical Reference Standards and Services segment | $0-100% | $1K0.0% | $1K— | $0— | $0— | |
| Consumer Products segment | $3.42M-10.5% | $3.82M+41.6% | $2.7M+7.4% | $2.51M+2.5% | $2.45M-0.3% | |
| Ingredients segment | $96K+540% | $15K-11.8% | $17K-62.2% | $45K+80.0% | $25K-78.8% | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| R&D by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | —— | $0— | $0— | $0— | |
| Consumer Products segment | $733K— | —— | $1.4M+19.8% | $1.17M+81.2% | $645K— | |
| Ingredients segment | $280K— | —— | $395K-0.8% | $398K+62.4% | $245K— | |
| Pharmaceuticals segment | $468K— | —— | —— | —— | $368K-16.3% | |
| G&A by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | —— | $0— | $0— | $0— | |
| Consumer Products segment | $0— | —— | $0— | $0— | $0— | |
| Ingredients segment | $0— | —— | $0— | $0— | $0— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— | |
| Advertising by Business | ||||||
| Analytical Reference Standards and Services segment | $0— | $0— | $0— | $0— | $0— | |
| Consumer Products segment | $3.29M-9.9% | $3.65M+16.1% | $3.15M+9.1% | $2.88M-3.2% | $2.98M-10.7% | |
| Ingredients segment | $0— | $0— | $0— | $0— | $0— | |
| Pharmaceuticals segment | $0— | —— | —— | —— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Niagen Bioscience, Inc. Common Stock break its business down?
- Niagen Bioscience, Inc. Common Stock (NAGE) reports net sales by business across 5 parts — Analytical Reference Standards and Services segment, Consumer Products segment, Corporate and other, Ingredients segment and Pharmaceuticals segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Niagen Bioscience, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Niagen Bioscience, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
